Kindeva
DRUG DELIVERY
Manufacturing More Tomorrows™

Low- GWP Propellants

Leading the way in sustainability

With clinical supply for HFA152a and HFO1234ze already available, commercial scale in 2024, and plans for expansion, Kindeva Drug Delivery accelerates your path to market while benefiting patients and the planet.

Clinical & commercial scale on your time line

We leverage our experience to help you prepare for evolving regulations and streamline the process of transitioning to low Global Warming Potential (GWP) propellants. We understand the importance of bringing your product to market as quickly as possible while preserving product quality and are primed to accelerate your time line.

A legacy of pulmonary & nasal expertise

Kindeva has consistently been at the forefront of innovation in pulmonary & nasal drug delivery. As the industry addresses the next shift in the form of green propellants, we are uniquely positioned to rise to the challenge.

Inventors of the pMDI

Created the first pMDI, kick-starting the evolution of inhaled therapies.

Leading the transition to CFC-free technology

Developed the first CFC-free pMDI and nasal pMDI in the 1990s.

Proven track record in generics

Launched the first FDA-approved generic of Symbicort® (Breyna™) in the U.S. and a generic of Seretide® (Sirdulpa™) in the U.K.

Next-generation propellants

Kindeva offers expertise in the two leading eco-friendly propellant options, which both significantly reduce environmental impact compared to current formulations. We can guide you in selecting and implementing the best option for your specific product needs.

Why now?

The pharmaceutical industry is facing a variety of regulations taking effect in the next decade that target f-gas emissions. By partnering with Kindeva now, you position your company at the forefront of this transition, ensuring compliance and demonstrating environmental leadership.

Built for a sustainable future

Kindeva's unparalleled expertise in respiratory drug delivery and green propellants makes us your ideal partner for this crucial transition. We offer comprehensive support from formulation to commercialization, with capabilities for both HFA152a and HFO1234ze.

Our scalable solutions meet your needs from clinical trials to full-scale production, backed by a proven track record in navigating complex regulatory landscapes.

Your therapy is a force for good.
Our expertise brings it into the world.

COMBINE FORCES WITH KINDEVA

Kindeva Drug Delivery is a leading global powerhouse CDMO for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dose. We are committed to manufacturing more tomorrows for our customers, colleagues, and patients around the world. We deliver unrivaled expertise across development, manufacturing, and comprehensive analytical services for a broad range of drug-delivery formats. Through strategic investments in cutting-edge technology, we proactively tackle critical industry challenges, including expanding aseptic injectable fill-finish capabilities and leading the way in green propellant initiatives. Combining forces with a diverse global client base, Kindeva operates state-of-the-art manufacturing, research, and development facilities across the U.S. and U.K.